Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rabbit Polyclonal (IgG) to Rat HTR1D / 5-HT1D Receptor
Rat, Human, Mouse
IHC - Paraffin, Western blot
Rabbit Polyclonal to Human HTR1D / 5-HT1D Receptor
IHC - Paraffin
Human HTR1D / 5-HT1D Receptor
Human (tested or 100% immunogen sequence identity)
Monkey, Dog (at least 90% immunogen sequence identity)
IHC - Paraffin (17 µg/ml)
Specificity and Use
Synthetic 16 amino acid peptide from N-terminal extracellular domain of human 5HT1D Receptor. Percent identity with other species by BLAST analysis: Human, Gorilla (100%); Monkey, Panda, Dog (94%); Horse (88%); Marmoset, Bat, Rabbit, Guinea pig (81%).
LS-E29105 - Liquid - 50 µg - $145.00
Immunizing peptide used to generate LS-A588. Useful for pre-absorption and neutralization of the antibody's antigen binding site.
Human 5HT1D Receptor. BLAST analysis of the peptide immunogen showed no homology with other human proteins.
PBS, less than 0.1% sodium azide.
Aliquot and store undiluted at -20°C or below for up to 1 year. Can be stored undiluted at 4°C for up to 1 month. Avoid freeze thaw cycles.
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.